Bristol-Myers Squibb Company — Opdivo in combination with AVD · Previously untreated Stage III or IV classical Hod.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (10/3/25) through T+5. Run-up high $62.37 on 2/27/26, low $42.6 on 11/5/25 (T-120 to T-1). FDA decision 3/20/26. Historical price action, not a forecast.